Zobrazeno 1 - 10
of 2 604
pro vyhledávání: '"onabotulinumtoxinA"'
Publikováno v:
JAAD Case Reports, Vol 51, Iss , Pp 56-58 (2024)
Externí odkaz:
https://doaj.org/article/ee7eb6da761d4d65b0d128b95e37a081
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
ObjectiveThis real-world study aimed to investigate how onabotulinumtoxinA affects the outcome of migraine, along with accompanying anxiety, depression, and bruxism among a group of patients with chronic migraine (CM) and define predictors of good re
Externí odkaz:
https://doaj.org/article/3f8cbf1b9e764b5a89feaa10fbacfd54
Autor:
María Pilar Navarro-Pérez, Vicente González-Quintanilla, Albert Muñoz-Vendrell, Elisabet Madrigal, Alicia Alpuente, Germán Latorre, Francis Molina, María José Monzón, Vicente Medrano, David García-Azorín, Carmen González-Oria, Ana Gago-Veiga, Fernando Velasco, Isabel Beltrán, Noemí Morollón, Javier Viguera, Javier Casas-Limón, Jaime Rodríguez-Vico, Elisa Cuadrado, Pablo Irimia, Fernando Iglesias, Ángel Luis Guerrero-Peral, Robert Belvís, Patricia Pozo-Rosich, Julio Pascual, Sonia Santos-Lasaosa
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundReal-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profil
Externí odkaz:
https://doaj.org/article/0a59df749dd94d6c9e8640bd61de3428
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
Initial urologic management of pediatric neurogenic lower urinary tract dysfunction (NLUTD) includes clean intermittent catheterization (CIC) regimen and use of anticholinergic or beta3 agonist medications. Historically, NLUTD that did not respond to
Externí odkaz:
https://doaj.org/article/cf2287c7dfcc46e39eb498543c8f7e1b
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-3 (2024)
Abstract In this critical review, we explore the study design, strengths and limitations of the paper: “Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.” The pa
Externí odkaz:
https://doaj.org/article/94c94321d38844549f5b7ae007e69189
Autor:
Ping-Hsuan Yu, Chung-Cheng Wang
Publikováno v:
Toxins, Vol 16, Iss 8, p 343 (2024)
Despite the efficacy of onabotulinumtoxinA, its safety profile remains a concern. This meta-analysis reviewed the major adverse events (AEs) associated with intravesical onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity (
Externí odkaz:
https://doaj.org/article/3d9b6dd403ce416ba712e18e425f68a3
Publikováno v:
Toxins, Vol 16, Iss 7, p 309 (2024)
OnabotulinumtoxinA (BT-A) is used in different medical fields for its beneficial effects. BT-A, a toxin originally produced by the bacterium Clostridium botulinum, is widely known for its ability to temporarily paralyze muscles by blocking the releas
Externí odkaz:
https://doaj.org/article/05873192ef0d4b58832ebedd7866905d
Autor:
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, Nicolai D. Ayasse, Daniel Serrano, Linda Davis, Katherine Sommer, Janette Contreras-De Lama, Richard B. Lipton
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-8 (2023)
Abstract Background Individuals using onabotulinumtoxinA as a preventive migraine treatment often use acute treatments for breakthrough attacks. Data on real-world effectiveness of the small-molecule calcitonin gene–related peptide (CGRP) receptor
Externí odkaz:
https://doaj.org/article/798c4497f6f544a296044c0039fea9f6
Autor:
Larry Charleston, Brian Talon, Christine Sullivan, Carlton Anderson, Steven Kymes, Stephane A. Regnier, Seema Soni-Brahmbhatt, Stephanie J. Nahas
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background To date, real-world evidence on persistence to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) or onabotulinumtoxinA have excluded eptinezumab. This retrospective cohort study was performed to compare
Externí odkaz:
https://doaj.org/article/bb268687fead4cd98685986f0097f51f